Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1359)	1/26/1999 2:26:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Monsanto Celebrex Prescribed Heavily in First Week, NDC Says Bloomberg News January 26, 1999, 1:27 p.m. ET Monsanto Celebrex Prescribed Heavily in First Week, NDC Says St. Louis, Jan. 26 (Bloomberg) -- Monsanto Co.'s new arthritis drug Celebrex could have one of the most successful introductions ever in the history of the U.S. drug industry, according to NDC Health Information Services. Celebrex, the first of a new class of painkillers that appear to have fewer side effects than existing drugs, had 1,047 prescriptions on Jan. 19, its first official day on the market, NDC said. Three days later, Celebrex had 3,411 prescriptions. Those numbers make Celebrex a rival to Warner-Lambert Co.'s cholesterol-reducing drug Lipitor. Lipitor's 1997 introduction set a record with 1,058 prescriptions the first day and 1,084 three week days later, NDC said. Lipitor's record was broken this year by Pfizer Inc.'s anti-impotence pill Viagra. ''The numbers are incredibly strong,'' said Hemant Shah, an independent analyst. Pfizer, considered one of the world's best marketers for pharmaceuticals, helps Warner-Lambert sell Lipitor and Monsanto sell Celebrex. Shares of St. Louis-based Monsanto rose 1/8 to 41 3/16 in early afternoon trading. Merck & Co., the world's biggest drugmaker, is seeking U.S. approval of its Vioxx drug, which would compete with Celebrex. --Kristin Jensen and Kerry Dooley in the Princeton newsroom (202)

To: Anthony Wong who wrote (1359)	1/26/1999 2:32:00 PM
From: Anthony Wong	Respond to of 1722

Eli Lilly Reiterated 'Strong Buy' at Gruntal, target $113 Bloomberg News January 26, 1999, 10:46 a.m. ET Princeton, New Jersey, Jan. 26 (Bloomberg Data) -- Eli Lilly & Co. (LLY US) was reiterated ''strong buy'' by analyst David F. Saks at Gruntal & Co. The 12-month target price is $113.00 per share. -- Sybil Carlson in Princeton, New Jersey, (609)279-3615